Primary prevention strategy for cardiovascular disease in Lithuania


Cardiovascular diseases are the main cause of premature death worldwide. More than half of deaths were caused by cardiovascular diseases in 2017 in Lithuania. Primary prevention programmes encourage both medical staff and general population to pay attention to potential health issues as well as attempt to eradicate risk factors causing cardiovascular diseases. “A Funding Programme for the Screening and Preventive Management of the High Cardiovascular Risk Individuals” published in Lithuania has been implemented as of 2006.

Analysis of the results of the programme shows that the prevalent cases of arterial hypertension are gradually declining. However, the prevalence of dyslipidaemia is still not decreasing. The prevalence of other modifiable cardiovascular disease risk factors has erratic trends with a slight overall decline. Consequently, mortality rate of cardiovascular diseases has decreased by more than one third among middle-age population over the past 10 years.

Having higher availability of the anti-hypertensive and anti-lipid medications already achieved, the future plans include the aim of further reducing elevated blood pressure and effectively treating dyslipidaemia. In order to implement a strategy that focuses on smoking prevention, promotion of healthy nutrition and physical activity, a significant contribution is required from the state authorities.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Health Information Centre, Institute of Hygiene, Ministry of Health of The Republic of Lithuania, Causes of death 2017, Vilnius 2018.

  • [2] WHO HFA Mortality database, 2009.

  • [3] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635–701.

  • [4] Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2016). The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J 2016;37:2315–81.

  • [5] Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for menscreened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–4.

  • [6] Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and longtermcoronary heart disease mortality in different cultures:twenty-five-year follow-up of the Seven Countries Study. JAMA 1995;274:131–6.

  • [7] MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–74.

  • [8] Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–38.

  • [9] Conroy RM., Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. on behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987– 1003.

  • [10] Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.

  • [11] Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Hear J 2018(39):3021–104.

  • [12] Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–68.

  • [13] Grabauskas V, Klumbienė J, Petkevičienė J, Petrauskienė A, Tamošiūnas A, Kriaučionienė V, et al. Lėtiniu˛ neinfekciniu˛ ligu˛ rizikos veiksniu˛ paplitimas tarp Lietuvos kaimišku˛ju˛ rajonu˛ gyventoju˛: CINDI programos tyrimas, 2007 m. Medicina (Kaunas) 2008;44(8):633–9.

  • [14] Lisauskienė I. Širdies ir kraujagysliu˛ sistem ˛a veikiančiu˛ vaistu˛ vartojimo ir sergamumo bei mirštamumo nuo šios sistemos ligu˛ kitimai Lietuvoje. Daktaro disertacija. Moksl. vadovė prof. J. Gulbinovič. – Vilnius, 2017, 213 p.

  • [15] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.

  • [16] Rinkūnienė E. Didelės kardiovaskulinės rizikos asmenu˛ nustatymo ir aktyvios pirminės prevencijos metodu optimizavimas. Daktaro disertacija. Mokslinė vadovė prof. Ž. Petrulionienė, moksl. konsultantas prof. A. Laucevičius. – Vilnius, 2014, 153 p.

  • [17] Baltic Statistics on Medicines 2013–2015.

  • [18] Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, Smith AL, Bauer DC, Newman AB, et al. Cigarette Smoking Exposure and Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study. Am Heart J 2012;164(2):236–42.

  • [19] Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: A systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol 2018;25(13):1437–51.

  • [20] Barua RS, Ambrose JA. Mechanisms of Coronary Thrombosis in Cigarette Smoke Exposure. Arterioscler Thromb Vasc Biol 2013;33:1460–7.

  • [21] Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91–111.

  • [22] Attard R, Dingli P, Doggen CJM, Cassar K, Farrugia R, Wettinger SB. The impact of passive and active smoking on inflammation, lipid profile and the risk of myocardial in- farction. Open Heart 2017;4(2):e000620.

  • [23] Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002;137(6):494–500.

  • [24] Hackshaw A., Morris JK, Boniface S, Tang JL, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018;360:j5855.

  • [25] Olin JW, Sealove BA. Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management. Mayo Clin Proc 2010;85(7):678–92.

  • [26] Shah RS., Cole JW. Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther 2010;8(7):917–32.

  • [27] He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease–a meta-analysis of epidemiologic studies. N Engl J Med 1999; 340(12):920–6.

  • [28] Gardner G, Halweil B. Underfed and overfed: the global epidemic of malnutrition. Washington, DC: Worldwatch Institute, 2000.

  • [29] Brimas G. Chirurginis nutukimo gydymas. Vilnius: Ciklonas, 2005, 352 p.

  • [30] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709–16.

  • [31] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation 2009;120(16):1640–5.

  • [32] Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55(13):1318–27.

  • [33] Slivovskaja I. Individualios aerobinės fizinės treniruotės veiksmingumas asmenims, kuriems nustatytas metabolinis sindromas. [The effectiveness of individual aerobic training in subjects with metabolic syndrome]. Daktaro disertacija. Moksl. vadovas prof. A. Juocevičius, moksl. konsultantė dr. L. Ryliškytė. – Vlnius, 2018, 200 p.

  • [34] Matheny M, McPheeters ML, Glasser A, Mercaldo N, Weaver RB, Jerome RN, et al. Systematic Review of Cardiovascular Disease Risk Assessment Tools. Evidence Syntheses/Technology Assessments, No. 85. 2011, 394 p.

  • [35] Grundy SM. Metabolic Syndrome Pandemic. Arterioscler Thromb Vasc Biol 2008; 28(4):629–36.

  • [36] Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, Hunink MG, et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J 2007;154(1):87–93.

  • [37] Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. Methods Inf Med 2007;46(1):43–9.

  • [38] Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The Metabolic Syndrome and Cardiovascular Risk. A Systematic Review and Meta-Analysis. Am Coll Cardiol 2010;56(14):1113–32.

  • [39] Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006l;27(13):1610–9.


Journal + Issues